Share on StockTwits

Analysts at Peel Hunt lifted their price objective on shares of Clinigen Group PLC (LON:CLIN) from GBX 690 ($11.53) to GBX 710 ($11.87) in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock. Peel Hunt’s target price indicates a potential upside of 76.33% from the company’s current price.

Shares of Clinigen Group PLC (LON:CLIN) opened at 428.919 on Wednesday. Clinigen Group PLC has a one year low of GBX 354.92 and a one year high of GBX 690.00. The stock has a 50-day moving average of GBX 378.4 and a 200-day moving average of GBX 469.7.

A number of other firms have also recently commented on CLIN. Analysts at Numis Securities Ltd reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Wednesday. They now have a GBX 650 ($10.87) price target on the stock. Separately, analysts at N+1 Singer reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Wednesday. They now have a GBX 439 ($7.34) price target on the stock. Finally, analysts at N+1 Singer initiated coverage on shares of Clinigen Group PLC in a research note on Thursday, August 7th. They set a “buy” rating and a GBX 439 ($7.34) price target on the stock. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of GBX 592.20 ($9.90).

Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.